Finance

Lists
Why is ELAN up 4,39%?
Dive Deeper
ELAN:NYSE
Elanco Animal Health Inc
23,54 US$
+4,39%
(+0,99) 1D
23,75 US$
+0,89% (+0,21)
Pre-market
Closed: 15 ოქტ, 16:00:07 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ELAN...
Open
22,83 US$
High
23,79 US$
Low
22,80 US$
Mkt. cap
11,76 მლრდ.
Avg. vol.
5,34 მლნ.
Volume
805,00
52-wk high
27,98 US$
52-wk low
19,40 US$
EPS
-0,42 US$
Beta
1,71
Shares outstanding
499,62 მლნ.
No. of employees
10 ათ.
Open
22,83 US$
High
23,79 US$
Low
22,80 US$
Mkt. cap
11,76 მლრდ.
Avg. vol.
5,34 მლნ.
Volume
805,00
52-wk high
27,98 US$
52-wk low
19,40 US$
EPS
-0,42 US$
Beta
1,71
Shares outstanding
499,62 მლნ.
No. of employees
10 ათ.
News stories
From web sources and news partners
Profile
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world. Wikipedia
About Elanco Animal Health Inc
CEOჯეფრი ენ სიმონს
Employees9,65 ათ.
Founded1954
Headquartersინდიანაპოლისი, ინდიანა, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Websiteelanco.com
Analyst ratings
Based on 12 analysts giving stock ratings to ELAN in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ELAN in the last 3 months.
Highest
Current 23,54 US$
34,00 US$ (+44,44%)
Average
31,44 US$ (+33,56%)
Lowest
26,00 US$ (+10,45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Buy
Reiterated
34,00 US$
+44,4%
10/01/2026
Jonathan Block
Stifel Nicolaus
Buy
Reiterated
-
-
09/18/2026
Steve Scala
TD Cowen
Buy
Reiterated
32,00 US$
+35,9%
08/25/2026
Glen Santangelo
Barclays
Buy
Maintained
30,00 US$
+27,4%
08/21/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
34,00 US$
+44,4%
08/12/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
08/12/2026
Chris Schott
J.P. Morgan
Buy
Maintained
-
-
08/11/2026
Erin Wright
Morgan Stanley
Hold
Reiterated
26,00 US$
+10,5%
08/10/2026
David Westenberg
Piper Sandler
Buy
Maintained
30,00 US$
+27,4%
08/10/2026
Andrea Alfonso
UBS
Buy
Maintained
33,00 US$
+40,2%
08/06/2026
Daniel Grosslight
Citi
Buy
Maintained
34,00 US$
+44,4%
08/06/2026
Scott Schoenhaus
KeyBanc
Buy
Maintained
30,00 US$
+27,4%
08/06/2026
Jasper Hellweg
Argus Research
Buy
Maintained
-
-
06/23/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
05/11/2026
Unknown Analyst
Jefferies
Buy
Maintained
30,00 US$
+27,4%
02/25/2026
Last report
5 აგვ. 2026
Fiscal period
Q2 2026
0,34 US$ / 0,27 US$
+26,46%beat
Revenue / Est. (USD)
1,37 მლრდ. / 1,31 მლრდ.
+4,16%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,14 მლრდ.
1,14 მლრდ.
1,37 მლრდ.
1,37 მლრდ.
Cost of goods sold
530,00 მლნ.
555,00 მლნ.
586,00 მლნ.
570,00 მლნ.
Cost of revenue
530,00 მლნ.
555,00 მლნ.
586,00 მლნ.
570,00 მლნ.
Research and development expenses
89,00 მლნ.
93,00 მლნ.
97,00 მლნ.
92,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
351,00 მლნ.
331,00 მლნ.
381,00 მლნ.
449,00 მლნ.
Operating expense
580,00 მლნ.
563,00 მლნ.
616,00 მლნ.
680,00 მლნ.
Total operating expenses
1,11 მლრდ.
1,12 მლრდ.
1,20 მლრდ.
1,25 მლრდ.
Operating income
27,00 მლნ.
26,00 მლნ.
169,00 მლნ.
118,00 მლნ.
Other non operating income
2,00 მლნ.
-15,00 მლნ.
-8,00 მლნ.
-11,00 მლნ.
EBT including unusual items
-50,00 მლნ.
-259,00 მლნ.
87,00 მლნ.
56,00 მლნ.
EBT excluding unusual items
-25,00 მლნ.
-37,00 მლნ.
103,00 მლნ.
65,00 მლნ.
Income tax expense
-16,00 მლნ.
17,00 მლნ.
30,00 მლნ.
2,00 მლნ.
Effective tax rate
32,00%
-6,56%
34,48%
3,57%
Other operating expenses
-
-
-
-
Net income
-34,00 მლნ.
-276,00 მლნ.
57,00 მლნ.
54,00 მლნ.
Net profit margin
-2,99%
-24,13%
4,16%
3,95%
Earnings per share
0,19
0,13
0,40
0,34
Interest and investment income
-
45,00 მლნ.
-
-
Interest expense
-52,00 მლნ.
-105,00 მლნ.
-57,00 მლნ.
-59,00 მლნ.
Net interest expenses
-52,00 მლნ.
-60,00 მლნ.
-57,00 მლნ.
-59,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
195,00 მლნ.
194,00 მლნ.
335,00 მლნ.
283,00 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები